Eighty-three patients were treated with hemosorption and essential phospholipids for coronary heart disease (CHD) and followed up for 3-5 years. The new approach to the treatment of CHD involves simultaneous removal of cholesterol-rich atherogenic lipoproteins by hemosorption and administration of essential phospholipids to increase cholesterol withdrawal from the cells. This combined treatment of coronary patients is shown to normalize cholesterol metabolism, improve microcirculation, increase stress tolerance and bring about an obvious clinical remission. The good clinical effect is corroborated by the results of bicycle ergometry and data on lipid spectrum, cholesterol metabolism, microcirculation and radio-isotope studies.